Norton CFC-free beclomethasone inhaler U.K. approval could come this year following patent victory.
Executive Summary
NORTON ANTICIPATES CFC-FREE BECLOMETHASONE INHALER U.K. APPROVAL IN LATE 1997 following a recent victory over 3M in the British patent courts. The U.K. court invalidated three European patents held by 3M which relate to the use of the CFC-free propellant P134a in metered dose inhalers. The ruling clears the way for Ivax' U.K. subsidiary Norton Healthcare to market its CFC-free beclomethasone inhaler in Great Britain once the product is approved by the Medicines Control Agency. Norton is predicting a U.K. launch in early 1998.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth